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Introduction
Atherosclerosis (ATS) is a chronic inflammatory disease 
characterized by formation of a plaque or lesion (also called atheroma) 
in the intimal layer of the arterial wall. Atherosclerotic plaque is 
composed of oxidized lipids and lipoproteins, inflammatory cell 
infiltrates, areas of cell death and fibrosis [1]. ATS is the leading cause 
of morbidity and mortality in developed nations. ATS is a dynamic 
disease evolving in time often-taking decades to develop advanced 
lesions responsible for clinical symptoms. Plaques may remain 
asymptomatic (subclinical disease), become occlusive (intermittent 
claudication or stable angina pectoris), or become thrombosis-prone 
(vulnerable) leading to athero-thrombotic events, such as myocardial 
infarction or stroke [2]. Pathogenesis of ATS is not yet fully elucidated; 
however clear evidence indicate that the Renin-Angiotensin System 
(RAS), and in particular its final product Angiotensin (Ang) II, play a 
pivotal role in atherogenesis.
The RAS is intimely involved in the maintenance of cardiovascular 
homeostasis, including regulation of blood pressure, blood flow, fluid 
volume and electrolyte balance. Secretion of renin is the first step 
in the RAS cascade. Renin is secreted in a regulated manner by the 
juxtaglomerular cells of the kidneys. Renin cleaves angiotensinogen, 
mainly synthesized in the liver, to form the inactive peptide Ang I. This 
is in turn converted by the Angiotensin Converting Enzyme (ACE) to 
form the biologically active peptide Ang II, the primary effector of the 
RAS. Ang II exerts its physiological actions through membrane-bound 
receptors of the G-protein coupled receptor family. The two main Ang 
II receptors are the Ang II receptor subtypes 1 (AT1) and 2 (AT2) 
which induce different signaling pathways and cellular responses. Pro-
atherosclerotic actions of Ang II are mediated by the AT1 receptor 
whereas the role of AT2 in ATS is still controversial. AT1 receptor is 
expressed in a variety of organs, blood vessel, and in bone marrow-
derived cells, such as macrophages and T cells [3,4]. 
The importance of Ang II in atherosclerotic cardiovascular disease 
has been widely demonstrated both indirectly and directly in humans 
and mouse models. Indeed, pharmacological inhibition of RAS system 
using ACE inhibitors or Angiotensin Receptor Blocker (ARBs) prevents 
or delays progression of ATS and reduces cardiovascular events in 
patients [5,6]. Along the same line, pharmacological inhibition or 
genetic inactivation of RAS prevents ATS development and stabilizes 
plaques in animal models of ATS [7-10]. Observational studies in 
humans have demonstrated that patients with high levels of circulating 
renin are at increased risk for myocardial infarction and other 
atherosclerotic cardiovascular events, suggesting a direct role for Ang 
II in promoting ATS [11,12]. During the past decades, specific mouse 
models with increased plasma concentrations of Ang II have been 
generated in hypercholesterolemic apolipoprotein E-deficient (ApoE-/-) 
and low-density lipoprotein-deficient (LDLr-/-) mice, allowing study of 
mechanism through which Ang II promotes ATS [13,14]. 
This review emphasizes the pro-atherosclerotic effects and 
underlying mechanisms of Ang II derived from mouse studies with 
Ang II-mediated ATS.
Mouse Models of Ang II-induced Atherosclerosis 
To define the direct role of Ang II in atherogenesis, non-
physiological and physiological models have been generated in ApoE-
/- or LDLr-/- mice. 
Non-physiological model: subcutaneous infusion of Ang II 
Daugherty et al. initiated studies in which Ang II was subcutaneously 
and chronically infused into ApoE-/- mice for 28 days by using osmotic 
pumps [13]. Results showed that Ang II promoted a significant 
increase in the extent of atherosclerotic lesion in the thoracic aorta, 
and that lesions were predominantly rich in lipid-laden macrophages 
and lymphocytes. Of note, authors reported no significant differences 
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between mice infused with increasing doses of Ang II (500 compared to 
1000 ng/min/Kg). Unexpectedly, mice also developed large abdominal 
aortic aneurysm. These vascular effects of Ang II occurred independent 
of  blood pressure elevations or changes in plasma lipid concentration 
[13]. Weiss et al. also showed that subcutaneous Ang II infusion 
induced-hypertension (8 weeks) specifically increased plaque size, 
in thoracic and abdominal aorta, as well as macrophage infiltration 
in ApoE-/- mice receiving standard chow or atherogenic diet [15]. 
Ni et al. have first demonstrated evidence of plaque vulnerability in 
response to Ang II infusion in ApoE-/- mice [16]. Authors reported 
that Ang II infusion into ApoE-/- mice not only increased plaque size 
confirming previous findings, but also promoted atherosclerotic 
plaque transformation to a more destabilized phenotype (increased 
macrophages and lipids, decreased collagen and smooth muscle cells 
content) [16]. Ang II continued to accelerate ATS in ApoE-/- mice even 
after discontinuation of Ang II infusion [17].
Physiological model: 2-Kidneys, 1-Clip renovascular 
hypertension
To study the contribution of Ang II in ATS in physiological 
conditions, Mazzolai et al. generated hypertensive ApoE-/- mice with 
endogenously increased (two-kidney, one clip, 2K1C) Ang II production 
(renovascular hypertension model) [14]. The 2K1C ApoE-/- mice are 
characterized by a pathophysiologically and continuously stimulated 
RAS with an endogenous increase in renin and consequently Ang II 
production secondary to unilateral renal artery clipping producing 
artery stenosis [18,19]. Contrary to models were high doses of Ang 
II are exogenously administered via minipumps as described above, 
the 2K1C ApoE-/- mouse model allows studying the effect of Ang II 
and hypertension on ATS development/progression in a context that 
is very much similar to that found in humans. In fact, in the 2K1C 
ApoE-/- mice, increased endogenous Ang II production is achieved 
through stimulation of renal renin secretion, as it occurs in humans, 
thus taking into account all the physiological regulatory mechanisms. 
Results revealed that 2K1C ApoE-/- mice presented increased lesion 
surface compared to normotensive ApoE-/- mice. However, extent of 
increased lesion surface was comparable to that observed in similarly 
hypertensive ApoE-/- mice but with normal circulating Ang II levels 
(1-kidney, 1-clip [1K1C] model) [14]. Nevertheless, 2K1C mice 
developed more advanced and vulnerable plaques than 1K1C mice 
(thinner fibrous cap, larger lipid core, increased macrophage content 
and decreased smooth muscle cells), confirming the hypothesis that 
Ang II mediates ATS independently of its hemodynamic effects but via 
a direct vascular effect.
Cellular and Molecular Mechanisms Responsible for 
the Pro-atherosclerotic Role of Ang II
Ang II modulates pro-atherosclerotic genes expression in 
vascular wall
Several studies have shown that Ang II increases expression of 
pro-atherosclerotic and/or decreases expression of anti-atherosclerotic 
genes in the aorta (Table 1). For example, Tham et al. reported a 
downregulation of the anti-inflammatory genes PPAR-α and PPAR-γ, 
and an upregulation of pro-inflammatory genes such as the MCP-1, the 
M-CSF, the E-selectin, the ICAM-1, the VCAM-1, the iNOS, and the 
COX-2 through a nuclear factor-kappaB-dependent pathway in aorta 
from ApoE-/- mice infused with Ang II [20]. Increased expression of 
other pro-inflammatory cytokines in response to Ang II has also been 
shown in aorta and culture of explanted aorta from mice with Ang II-
induced ATS [16,21]. More recently, it has been shown that Ang II up-
regulated extracellular matrix metalloproteinase inducer (EMMPRIN) 
expression in aortic plaques from ApoE-/- mice, which could play a role 
in plaque destabilization [22].
Ang II induces Th1/Th2 imbalance 
Inflammatory cells, including CD4 T lymphocytes, are commonly 
found in ATS plaque during all stages of the disease [1]. CD4+ T cell 
subtype Th1 (pro-inflammatory cells) plays a major role in ATS while 
the role of CD4+ T cell subtype Th2 (anti-inflammatory cells) is still 
unclear [1]. Mazzolai et al. investigated for the first time the specific 
role of Th1/Th2 balance in Ang II-induced ATS [14]. Results showed 
that IFN-γ production (the Th1 signature cytokine) from spleen 
lymphocytes was stimulated in ApoE-/- 2K1C one week after renal 
artery clipping whereas IL-4 production (the Th2 signature cytokine) 
remained unchanged [14]. These findings indicate that Ang II skews 
the Th1/Th2 balance towards a pro-inflammatory Th1 profile in the 
early phase of ATS process, which may induce plaque vulnerability. 
Other mechanisms
Recent studies using pharmacological or genetic approaches in 
Ang II-infused hypercholesterolemic mice, showed that numerous 
factors/proteins are involved in Ang II-induced ATS, including 
myeloid differentiation factor 88 (a mediator of signaling cascade 
that directly influences leukocytes involved in innate immunity and 
has indirect effects on adaptive immunity) [23], endothelin-1 [24], 
or receptor-associated protein (a regulator of low density lipoprotein 
receptor-related protein 1) [25]. Endothelial dysfunction is a critical 
element in the pathogenesis of atherosclerotic disease. Impaired aortic 
endothelium-dependent relaxation as well as decreased eNOS protein 
phosphorylation has been recently demonstrated in ApoE-/- mice-
infused Ang II [26]. 
Pro-atheroscleotic genes Effect of Ang II
monocyte chemotactic protein-1 (MCP-1) upregulation
macrophage-colony stimulating factor (M-CSF) upregulation
endothelial-selectin (E-selectin) upregulation
intercellular adhesion molecule-1 (ICAM-1) upregulation
vascular cell adhesion molecule-1 (VCAM-1) upregulation
inducible nitric oxide synthase (iNOS) upregulation
cyclooxygenase-2 (COX-2) upregulation
tumor necrosis factor-α (TNF-α) upregulation
interleukin-6 (IL-6) upregulation
interleukin-1β (IL-1β) upregulation
transforming growth factor β1 (TGF-β1) upregulation
regulated upon Activation, Normal T cell Expressed and 
Secreted (RANTES) upregulation
monocyte chemoattractant protein-1 (MCP-1) upregulation
C-C chemokine receptor type 1 (CCR1) upregulation
C-C chemokine receptor type 2 (CCR2) upregulation
C-C chemokine receptor type 3 (CCR3) upregulation
granulocyte colony-stimulating factor (G-CSF) upregulation
granulocyte macrophage colony-stimulating factor (GM-CSF) upregulation
interleukin-12 IL-12 (P40) upregulation
macrophage inflammatory protein 1-α (MIP-1α) upregulation
interferon-γ (IFN-γ) Upregulation
Anti-atheroscleotic genes Effect of Ang II
peroxisome proliferator-activated receptor-α (PPAR-α) Downregulation
peroxisome proliferator-activated receptor-γ (PPAR-γ) downregulation
Table 1: Effects of Angiotensin II on pro-atherosclerotic and anti-atherosclerotic 
genes expression in mouse aorta [16,20,21].
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Conclusions and Perspectives
Mouse models with high circulating Ang II levels provide direct 
evidence that Ang II is a local mediator of plaque development and 
vulnerability. Modulation of Th1/Th2 phenotype appears to be a major 
downstream atherosclerotic mechanism of Ang II. Further research is 
needed to determine the time course of Th1/Th2 modulation in ATS 
process. 
Th17 has been recently identified as the third CD4 T cell subset, and 
has been suggested  to play an important role in Ang II-induced ATS 
[27]. However, no experimental data are available yet to substantiate 
this hypothesis. 
Similarly, to CD4 T cells, macrophages can polarize into two 
different subsets: classically pro-inflammatory M1 macrophages, driven 
by Th1 cytokines, or alternatively anti-inflammatory M2 macrophages, 
driven by Th2 cytokines. Although recent evidence indicates that the 
macrophage polarization balance affects pathogenesis, evolution, and 
complications of ATS [28], its specific implication in Ang II-induced 
ATS is unknown. 
In conclusion, although there are good experimental proofs 
demonstrating a pro-atherosclerotic role of Ang II, the precise 
mechanisms whereby Ang II exerts its actions need further clarification. 
Ang II-dependent signaling pathways may refer to a complex and multi 
factorial process including, at least in part, the involvement of various 
immuno-inflammatory cell types, and a pro-and anti-inflammatory 
cytokines network. More work is needed to define the specific networks 
of pathways activated by Ang II. 
Clinical Applications
A better understanding of cellular and molecular mechanisms 
underlying how Ang II mediates atherosclerosis and plaque vulnerability 
may help develop new and more selective therapeutic strategies aiming 
at preventing Ang II-related atherosclerotic cardiovascular disease. 
Results reported in mouse studies, if confirmed in clinical 
studies, should have clinical implications. In fact, hypertensive or 
nonhypertensive patients presenting with clinical or subclinical 
atherosclerosis would benefit from pharmacological blockade of key 
pro-atherosclerotic Angiotensin II-dependent signaling pathways. 
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